EntryPoint Capital’s AbCellera Biologics ABCL Stock Holding History

EntryPoint Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-89,570	Closed	-$307K	–	646
2025 Q2	$307K	Sell	89,570 -98,252	-52%	-$245K	0.15%	265
2025 Q1	$419K	Buy	187,822 +19,140	+11%	+$54.9K	0.19%	170
2024 Q4	$494K	Buy	168,682 +51,524	+44%	+$143K	0.21%	110
2024 Q3	$305K	Buy	117,158 +89,067	+317%	+$247K	0.17%	242
2024 Q2	$83.1K	Buy	28,091 +24,363	+654%	+$92.2K	0.04%	900
2024 Q1	$16.9K	Buy	+3,728	New	+$19K	0.02%	1141

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

EntryPoint Capital's ABCL Position: Q3 2025 in Review

EntryPoint Capital sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 89,570 shares — an estimated $307K sold.

EntryPoint Capital first reported a position in ABCL in Q1 2024 and held it in 6 quarters. The position peaked at $494K in Q4 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

EntryPoint Capital reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 89,570 AbCellera Biologics shares in Q3 2025, an estimated $307K.
EntryPoint Capital first reported a position in AbCellera Biologics in Q1 2024 and held it in 6 quarters.
EntryPoint Capital's AbCellera Biologics position peaked at $494K in Q4 2024.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.